$LYEL

Lyell Immunopharma, Inc. (LYEL): Submission of Matters to a Vote of Security Holders

Lyell Immunopharma, Inc. (LYEL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001806952 0001806952 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

Original reporting
Published Jun 15, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LYEL
Neutral
high confidence
Mentioned
$LYEL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LYELNeutralLow
01

Why it matters

The disclosure confirms quorum and voting results for three proposals: electing Class II directors, ratifying Ernst & Young LLP as auditor, and an advisory say-on-pay vote.

02

Market read

This is a routine governance update with no new operating or financial catalyst in the provided text.

03

What to watch

Traders may instead focus on any concurrent proxy items (not included here) such as proposals, compensation changes, or director background shifts.

Relevance 6/10Novelty 2/10Timing: Filed June 15, 2026 for a June 10, 2026 annual meeting vote

Background

The filing is an SEC Form 8-K reporting certified results from Lyell Immunopharma’s June 10, 2026 virtual annual meeting.

Company-level read

Ticker impact

$LYELNeutralHigh confidence
Context

Lyell Immunopharma reported 2026 annual meeting voting results, including director elections and advisory say-on-pay outcomes.

Expected impact

Low likelihood of a sustained price move based solely on these vote tallies.

Evidence & confidence

The 8-K discloses standard governance items (board election, auditor ratification, advisory compensation vote) without new financial guidance, transactions, or regulatory actions.

Market effects

No clear sector read-through; governance vote mechanics are company-specific.

Minimal; US-listed biotech governance filing.

None indicated.

Counterpoint

If vote outcomes were unusually contentious, it could hint at shareholder dissatisfaction, but the filing provides no narrative or threshold triggers.

Key entities

  • Lyell Immunopharma, Inc.

    Company reporting annual meeting vote results on Form 8-K (Item 5.07).

  • Ernst & Young LLP

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

Related articles

$LYELMed

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

Lyell Immunopharma, Inc. (LYEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 • PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-

$KEYMedAI 8/10

KeyCorp issued $1,000,000,000 aggregate principal amount of its 5.889% Fixed-to-Floating Rate Senior Medium Term Notes, Series U, due November 2, 2032

KEYCORP /NEW/ (KEY) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 2, 2026, KeyCorp (the “Company”) issued $1,000,000,000 aggregate principal amount of its 5.889% Fixed-to-Floating Rate Senior Medium Term Notes, Series U, due November 2, 2032 (the “Notes”). The Notes were registered under the Securities Act of

$FTAIHighAI 8/10

FTAI Aviation Ltd. announced that FTAI Aviation Investors LLC, its subsidiary, priced its previously announced private offering of $1.0 billion aggregate…

FTAI Aviation Ltd. (FTAI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 2, 2026, FTAI Aviation Ltd. (“FTAI Aviation” and, together with its consolidated subsidiaries, the “Company,” “we,” “us” or “our”) announced that FTAI Aviation Investors LLC, its subsidiary (the “FTAI LLC” or the “Issuer”), priced its previousl

$CEMed

Sales rose 6% year over year but fell 7% from the prior quarter at Celanese.

Celanese reported a 6% year-over-year sales increase but a 7% quarterly decline. Q3 2026 net sales were $2.56B, with operating profit at $198M. The company expects to generate over $1B in cash by year-end 2026 and aims for a net debt-to-EBITDA ratio of 4.7x. Celanese announced strategic initiatives, including a joint venture sale and a partnership for robotics components.

$CARMed

Avis Budget Car Rental, LLC and Avis Budget Finance, Inc., each a wholly-owned subsidiary of Avis Budget Group, Inc., delivered a notice for the redemption…

AVIS BUDGET GROUP, INC. (CAR) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 2, 2026, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc., each a wholly-owned subsidiary of Avis Budget Group, Inc., delivered a notice for the redemption of all $350,000,000 aggregate principal amount outstanding of their 5.750% Sen